MC(C5)-Val-Cit

MC(C5)-Val-Cit is a specialized carbohydrate-based linker designed for advanced bioconjugation and targeted delivery systems in biochemical research and pharmaceutical development. Featuring a maleimidocaproyl (MC) moiety linked to a pentanoic acid (C5) spacer and a valine-citrulline (Val-Cit) dipeptide, this compound enables precise and stable attachment of payloads to biomolecules through thiol-reactive chemistry. Its unique structure facilitates controlled release mechanisms, making it highly valuable for applications requiring selective cleavage and targeted payload delivery. The hydrophilic nature and engineered stability of MC(C5)-Val-Cit contribute to its versatility across a broad spectrum of research environments, supporting the development of innovative molecular tools and therapeutics.

Antibody-Drug Conjugate (ADC) Development: MC(C5)-Val-Cit serves as a critical component in the synthesis of antibody-drug conjugates, where its cleavable linker design allows for the stable attachment of cytotoxic agents to monoclonal antibodies. Upon internalization into target cells, the Val-Cit dipeptide is specifically cleaved by lysosomal proteases, resulting in the efficient release of the active drug. This mechanism enhances the selectivity and efficacy of ADCs, minimizing off-target effects and improving therapeutic indices in preclinical research models. The MC moiety's thiol-reactive properties ensure compatibility with various antibody formats, enabling researchers to optimize conjugation strategies for specific targets and payloads.

Targeted Protein Modification: The maleimide functionality in MC(C5)-Val-Cit enables site-specific conjugation to cysteine residues on proteins, facilitating the creation of homogenous protein conjugates for structural and functional studies. This linker system is particularly valuable in producing modified enzymes, fluorescently labeled proteins, or affinity reagents with predictable release profiles. By incorporating the Val-Cit sequence, researchers can design conjugates that undergo controlled cleavage in protease-rich environments, allowing for precise investigation of protein function, localization, and interactions under dynamic biological conditions.

Payload Delivery Systems: As a modular linker, MC(C5)-Val-Cit is instrumental in constructing payload delivery systems beyond antibody conjugates, including peptide-drug conjugates and nanoparticle-based carriers. Its cleavable nature ensures that therapeutic or diagnostic agents are released in response to specific enzymatic triggers, enhancing the selective targeting of cells or tissues of interest. The pentanoic acid spacer provides optimal flexibility and spacing between the carrier and the payload, reducing steric hindrance and improving the overall efficiency of delivery. This adaptability supports the development of next-generation delivery vehicles for a wide range of bioactive compounds.

Biomarker Detection and Imaging: In the field of molecular imaging and biomarker detection, MC(C5)-Val-Cit is utilized to create cleavable probes that release reporter molecules upon encountering disease-associated protease activity. This strategy enables the real-time monitoring of biological processes, disease progression, or therapeutic response in vitro and in vivo. The linker's specificity for protease-mediated cleavage ensures high signal-to-noise ratios and minimal background interference, making it a valuable tool for the development of sensitive and selective imaging agents in research applications.

Controlled Release Research: Researchers leverage MC(C5)-Val-Cit in studies focusing on controlled release mechanisms within complex biological environments. Its engineered cleavage sequence allows for the temporal and spatial regulation of payload liberation, supporting investigations into drug activation, enzymatic degradation pathways, and the optimization of release kinetics. This application is particularly relevant for the design of smart therapeutics and responsive biomaterials, where precise control over the timing and location of active compound release is essential for maximizing efficacy and minimizing adverse effects.

Peptide-Drug Conjugate Engineering: In peptide-drug conjugate development, MC(C5)-Val-Cit offers a robust platform for linking small molecule drugs to targeting peptides, combining the advantages of peptide specificity with controlled drug release. Its modular design supports the exploration of diverse peptide sequences and payloads, enabling the creation of tailored conjugates for research in targeted therapy, receptor mapping, and functional screening. The Val-Cit dipeptide's susceptibility to enzymatic cleavage ensures that the drug is selectively released in target environments, thereby enhancing the utility of peptide-based delivery systems in both basic and applied research settings.

1. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

4. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

5. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line